Daniel Furst

Credentials: · · · ·

History

Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases · U01
Contact PI · $1.1M · University of California Los Angeles
2007–2012
Oral Cyclophosphamide vs Oral Placebo in Ssc Alveolitis
National Heart, Lung, and Blood Institute · U01
Contact PI · $95.9K · Benaroya Research Inst at Virginia Mason
1999–2002
Analysis of Controlled Trial of Chlorambucil vs. Placebo
Food and Drug Administration · R01
Contact PI · $102.3K · University of Iowa
1983–1986
General Clinical Research Center
National Center for Research Resources · M01
Project lead · University of California Los Angeles

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
Principal investigator · Completed · Phase 1, Phase 2
University of California, Los Angeles
2007–2008
Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Study chair · Completed
Duke University
2012–2013
Scleroderma: Cyclophosphamide or Transplantation
Study chair · Completed · Phase 2, Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
2005–2016
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Study chair · Completed
National Institute of Allergy and Infectious Diseases (NIAID)
2005–2016